This study focuses on treating patients with lower respiratory tract viral infections who require breathing support through a ventilator. The study will test a medication called SNG001, which contains interferon beta-1a and is given through inhalation using a nebulizer (a device that turns liquid medicine into a fine mist that can be breathed in). The study will include patients who have various respiratory viruses, including influenza, respiratory syncytial virus, rhinovirus, adenovirus, parainfluenza, human metapneumovirus, and coronaviruses.
The purpose of this research is to determine if SNG001 is safe and effective for treating patients on ventilators who have viral respiratory infections. The study is divided into two parts – the first part will look at the safety of the treatment, while the second part will compare SNG001 to placebo to see how well it works. Patients will receive either SNG001 or placebo through a nebulizer while they are on a ventilator.
During the study, doctors will monitor patients’ recovery, including how long they need to stay in the intensive care unit, how long they need ventilator support, and whether the treatment helps them recover from their viral infection. The treatment period will last up to 14 days, and patients will be monitored for up to 28 days to assess their recovery.
Belgium 
France 
Spain 
The Netherlands 